[{"id":"83e3e01a-2bbf-4af8-809b-9ed445e92390","acronym":"","url":"https://clinicaltrials.gov/study/NCT00085124","created_at":"2021-01-18T00:14:46.895Z","updated_at":"2024-07-02T16:35:00.079Z","phase":"Phase 3","brief_title":"Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia","source_id_and_acronym":"NCT00085124","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • daunorubicin • Genasense (oblimersen)"],"overall_status":"Completed","enrollment":" Enrollment 500","initiation":"Initiation: 12/01/2003","start_date":" 12/01/2003","primary_txt":" Primary completion: 06/01/2007","primary_completion_date":" 06/01/2007","study_txt":"","study_completion_date":"","last_update_posted":"2024-05-30"},{"id":"31f15265-1220-4c1c-9b23-9c70cc30767a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00049374","created_at":"2021-01-18T00:05:03.471Z","updated_at":"2024-07-02T16:36:54.498Z","phase":"Phase 2","brief_title":"Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT00049374","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • thalidomide • Genasense (oblimersen)"],"overall_status":"Completed","enrollment":"","initiation":"Initiation: 09/01/2002","start_date":" 09/01/2002","primary_txt":" Primary completion: 01/01/2006","primary_completion_date":" 01/01/2006","study_txt":" Completion: 01/01/2006","study_completion_date":" 01/01/2006","last_update_posted":"2019-10-17"}]